Microscopic image showing brown, antibody-based staining of keratin 17 (K17) in bladder cancer.
Credit: Shroyer Lab, Stony Brook University
A novel urine screening test that uses a protein, keratin 17 (K17), as a cancer biomarker reveals the test detects the presence of new or recurrent cases of bladder cancer.
The methodology behind the test stems from research at Stony Brook University led by Kenneth Shroyer, MD, PhD. A study that details the finding of the test is published in the American Journal of Clinical Pathology.
Some 81,000 cases of bladder cancer are diagnosed in the United States each year according to the American Cancer Society. Accurate detection of bladder cancer, or urothelial carcinoma (UC), is often difficult, expensive and involves invasive testing. Going forward, this new method, based on the detection of K17 in urine specimens, could help guide treatment by improving diagnostic accuracy.
“It is important to find new biomarkers to more accurately detect UC since standard methods used in most cytology labs are based primarily on microscopic details that do not always clearly distinguish cancer from benign cells,” explains Dr. Shroyer, the Marvin Kuschner Professor and Chair of Pathology at the Renaissance School of Medicine at Stony Brook University and inventor of the K17 test.
Previously, Dr. Shroyer and his colleague, Dr. Luisa Escobar-Hoyos (an Assistant Professor at Yale), co-directed a team of Stony Brook University students and collaborators to demonstrate that K17 is a highly sensitive and specific biomarker for UC in tissue biopsy and surgical specimens. The current published study builds on these findings to show that K17 testing could also be performed as a non-invasive test on urine specimens.
Using various urine sample sets, the Stony Brook team found that the urine K17 test detected UC in 35/36 (97 percent) of cases that were confirmed by biopsy, including 100 percent of cases with high-grade UC.
From these results and other findings based on the testing, the authors conclude that K17 testing is a highly sensitive and specific diagnostic test for initial screening and for detection of recurrence across all grades of UC.
Dr. Shroyer and his colleagues believe the potential of this test as a non-invasive way to detect UC will help to transform not only diagnostic practices but earlier treatment intervention and prognosis of UC.
The K17 test is being developed commercially by KDx Diagnostics, Inc., a start-up biotech company, which has a license with The Research Foundation for The State University of New York.
Recently, KDx has been awarded a breakthrough device designation from the Food and Drug Administration for its assay test with K17.
For years, the Shroyer lab, in collaboration with Dr. Luisa Escobar-Hoyos, has been exploring K17 as a biomarker for various cancers, including UC and pancreatic cancer. Furthermore, the research team continues to advance the understanding of how K17, once thought to be only a structural protein, fundamentally impacts numerous hallmarks of cancer.
Original Article: New Non-Invasive Test Can Detect Bladder Cancer
More from: Stony Brook University | Yale University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Non-invasive test for bladder cancer
- Vesica Health rolls out new test for bladder cancer detection
The AssureMDx test aids in identifying patients at an increased risk for bladder cancer, allowing for timely urological referrals.
- Urine Test Decreases Cystoscopies in Patients With Bladder Cancer
A urine test was shown to decrease the need for invasive cystoscopies in patients with non-muscle-invasive bladder cancer.
- Urine-based test detects head and neck cancer
While the initial study focused on head and neck cancer, the team also analyzed urine samples of people with other cancers, such as breast and acute myeloid leukemia, and found that ultrashort ...
- Testing Urine for Prostate Cancer: The Crystal Ball in Your Bladder
Ever felt like you're just waiting for the other shoe to drop, especially regarding medical test results? Francis Collins, the former NIH director, found himself in that situation, dancing the ...
- Researchers discover urine-based test to detect head and neck cancer
The test could potentially facilitate early detection of this cancer type, which currently does not have a reliable screening method. Researchers from the University of Michigan Health Rogel ...
Go deeper with Google Headlines on:
Non-invasive test for bladder cancer
[google_news title=”” keyword=”non-invasive test for bladder cancer” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Bladder cancer
- Man whose cancer kept coming back says his determination to 'never give up' is why he is still here today
Saheed Badmus, 44, moved to the UK from Nigeria to undergo a full bladder reconstruction - his family are now trying to raise £65,000 to pay for the cost of the operation ...
- May is Bladder Cancer Awareness month
According to the American Cancer Society, bladder cancer makes up about 4% of cancers in the United States. Dr. Patrick Tenbrink with Jupiter Medical Center stopped by our studio to talk more about ...
- TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer
Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 exhibited a high complete response rate to the treatment.
- Buy Rating Affirmed: Johnson & Johnson’s Bladder Cancer Treatments Poised to Transform Standard of Care
Leerink Partners analyst David Risinger has reiterated their bullish stance on JNJ stock, giving a Buy rating on May 6. David Risinger has ...
- Most BCG-Unresponsive Bladder Cancer Responds to TAR-200 Treatment
A novel delivery system of gemcitabine called TAR-200 led to promising responses in certain patients with non-muscle-invasive bladder cancer. A new delivery system of gemcitabine called TAR-200 ...
Go deeper with Google Headlines on:
Bladder cancer
[google_news title=”” keyword=”bladder cancer” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]